BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 19, 2001
View Archived Issues
Allos Therapeutics reports year-end 2000 results, goals for 2001
Read More
Status of development programs at OSI
Read More
BioTime and Organon Teknika establish exclusive license agreement for Hextend
Read More
MicroHeart obtains exclusive license to angiogenic/antiinflammatory compound
Read More
Neurocrine reports additional positive clinical results with NBI-34060 for insomnia
Read More
Visicol to be copromoted by Procter & Gamble
Read More
EntreMed expands phase II 2ME2 program to include prostate cancer
Read More
AEterna enters two commercialization alliances for Neovastat in Europe
Read More
Adjunctive therapy with rufinamide safe, effective and devoid of significant PK interactions
Read More
Antihistaminic equivalence of cetirizine and levocetirizine demonstrated in healthy volunteers
Read More
Phase II trial establishes safety and optimal dose of PVAC psoriasis treatment
Read More
Potential of PPARgamma agonists in stroke demonstrated in rats using troglitazone
Read More
Neuroprotective Ca2+ channel blocker acts by attenuating ischemia-induced glutamate release
Read More
Idun presents inhibitors of ICE/ced-3 cysteine proteases
Read More
Selective human PPARdelta receptor agonists and their use in type 2 diabetes and related disorders
Read More
VLA-4 antagonists with oral activity emerge from Daiichi/Pharmacopeia collaboration
Read More
Cytokine inhibitors in the Merck pipeline
Read More
New Aventis compounds block Kv1.5 potassium channels
Read More
Janssen devotes significant resources to discovery of antiviral agents
Read More
Potential new antiulcer agent DBM-819 characterized in vitro and in vivo
Read More
Positive hemodynamic results reported in phase III trial of tezosentan
Read More
Cyclacel to evaluate lead CDK2 inhibitor in phase I
Read More
TMP-substituted phenazine B-4128: antimycobacterial activity and mechanism of action
Read More
Akzo Nobel receives offer from bioMerieux for diagnostics business
Read More
OP-1 Implant recommended for approval in Australia
Read More
Excellent antianaerobic activity demonstrated for BMS-284756
Read More
CytRx begins research project with potential treatment for spinal cord injury
Read More